NCT06359041 - RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions

Generalized Myasthenia Gravis (gMG)

Interventions

BIOLOGICAL

CABA-201

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Trial Locations (14)

10032

RECRUITING

Columbia University, New York

14642

RECRUITING

University of Rochester Medical Center, Rochester

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

55905

RECRUITING

Mayo Clinic - Rochester, Rochester

60611

RECRUITING

Northwestern Memorial Hospital, Chicago

66160

RECRUITING

University of Kansas Medical Center, Kansas City

77030

RECRUITING

Houston Methodist Hospital, Houston

80045

RECRUITING

University of Colorado, Aurora

92868

RECRUITING

University of California Irvine, Orange

94143

RECRUITING

University of California, San Francisco, San Francisco

95817

RECRUITING

UC Davis, Department of Neurology, Sacramento

97239

RECRUITING

Oregon Health & Science University, Portland

98122

RECRUITING

Swedish Neuroscience Research, Seattle

01655

RECRUITING

University of Massachusetts Chan Medical School, Worcester